High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pisetta Chiara, Chillè Claudia, Pelizzari Giovanni, Pigozzi Marie Graciella, Salvetti Massimo, Paini Anna, Muiesan Maria Lorenza, De Ciuceis Carolina, Ricci Chiara, Rizzoni Damiano
Аннотация
INTRODUCTION: The study aimed to investigate, in patients with primary non-alcoholic fatty liver disease (NAFLD), the presence of possible relationships between the degree of steatosis or fibrosis and the individual cardiovascular risk and possibly whether a difference between those various methods exists.
METHODS: Thirty-four adult patients with primary NAFLD were included in this study. Clinical evaluation included an ultrasonographic examination for the determination of the severity of steatosis. Two different clinical indirect indexes of the severity of hepatic fibrosis were used: the FIB-4 score and the NAFLD fibrosis score. Then, the individual cardiovascular 10-years risk according to 5 different scores: "Progetto Cuore" of the Italian Institute of Health, Framingham score 2004-ATP III, Framingham risk score 2008, ACC/AHA ASCVD risk score 2013, ACC/AHA ASCV risk score new model score 2 were estimated.
RESULTS: The severity of steatosis evaluated by ultrasonography was significantly correlated only with ACC/AHA ASCVD RISK 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham 2008 risk scores. The severity of fibrosis evaluated by the FIB-4 score or with NAFLD fibrosis score was significantly correlated only with cardiovascular risk evaluated with ACC/AHA ASCVD 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham risk score 2008.
CONCLUSIONS: Some of the methods for the estimation of cardiovascular risk (ACC/AHA ASCVD 2013, new model 2 2018, and, also Framingham score 2008) have a clear advantage over Framingham score 2004 and "Progetto Cuore" of the Italian Institute of Health in terms of correlation with the severity of NAFLD. They are, therefore, more clinically useful.
METHODS: Thirty-four adult patients with primary NAFLD were included in this study. Clinical evaluation included an ultrasonographic examination for the determination of the severity of steatosis. Two different clinical indirect indexes of the severity of hepatic fibrosis were used: the FIB-4 score and the NAFLD fibrosis score. Then, the individual cardiovascular 10-years risk according to 5 different scores: "Progetto Cuore" of the Italian Institute of Health, Framingham score 2004-ATP III, Framingham risk score 2008, ACC/AHA ASCVD risk score 2013, ACC/AHA ASCV risk score new model score 2 were estimated.
RESULTS: The severity of steatosis evaluated by ultrasonography was significantly correlated only with ACC/AHA ASCVD RISK 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham 2008 risk scores. The severity of fibrosis evaluated by the FIB-4 score or with NAFLD fibrosis score was significantly correlated only with cardiovascular risk evaluated with ACC/AHA ASCVD 2013, ACC/AHA ASCVD New Model 2 2018 and Framingham risk score 2008.
CONCLUSIONS: Some of the methods for the estimation of cardiovascular risk (ACC/AHA ASCVD 2013, new model 2 2018, and, also Framingham score 2008) have a clear advantage over Framingham score 2004 and "Progetto Cuore" of the Italian Institute of Health in terms of correlation with the severity of NAFLD. They are, therefore, more clinically useful.